多药耐药的Acinetobacter baumannii:一个的,对现代医疗保健存在的威胁
Rahul Maitra1, Deepanshi Saxena1, Swechchha Singh1,2
1Division of Molecular Microbiology and Immunology, CSIR-Central Drug Research Institute, Sector 10, Janakipuram Extension, Sitapur Road, Lucknow 226031, Uttar Pradesh, India.
宝曼尼菌 (Acinetobacter baumannii) 是导致严重感染的关键优先病原体. 本综述详细介绍了其流行病学,耐药性和有限的治疗选择,强调迫切需要针对抗卡巴耐药菌株的新策略.
科学领域:
- 微生物学 微生物学
- 传染性疾病 传染性疾病
- 公共卫生 公共卫生
背景情况:
- 宝曼尼菌 (Acinetobacter baumannii) 是一种格拉姆阴性病原体,导致医院和社区获得的感染.
- 多种耐药菌株的增加,特别是耐卡巴胺的Acinetobacter baumannii (CRAB),对全球健康构成重大威胁.
- 高传播率和有限的治疗选择有助于高发病率和死亡率.
研究的目的:
- 提供关于Acinetobacter baumannii的全面审查.
- 阐明病原体的全球流行病学,病原体发生和宿主-病原体相互作用.
- 讨论当前的治疗策略和抗菌素耐药性的机制.
主要方法:
- 全球流行病学的文献综述.
- 分析病原和宿主-病原相互作用研究.
- 检查抗微生物药物耐药性机制和治疗选择.
主要成果:
- 宝曼尼菌 (Acinetobacter baumannii) 是世卫组织的关键优先病原体,具有中度至高的传染性.
- 耐卡巴胺菌株 (CRAB) 的治疗选择有限.
- 该综述综合了有关疾病,耐药性和治疗的信息.
结论:
- 对Acinetobacter baumannii的整体理解对于打击其传播和影响至关重要.
- 由于CRAB的出现,迫切需要开发新的治疗方法.
- 有效的策略需要解决流行病学,病原体和耐药机制.
更多相关视频
07:41Author Spotlight: A Comprehensive Protocol for Acinetobacter Biofilm Quantification, Assessment, and Visualization
Published on: August 4, 2023
07:59Rapid and Specific Detection of Acinetobacter baumannii Infections Using a Recombinase Polymerase Amplification/Cas12a-based System
Published on: April 25, 2025
相关概念视频
Development of Antibiotic Resistance
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Defense Against Bacterial Pathogens
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
Acute Pyelonephritis II: Diagnostic Studies and Management
Antibiotic Selection
Gene Regulation in Microbial Communities: Quorum Sensing
